ProfileGDS5678 / 1438332_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 55% 54% 55% 53% 54% 55% 53% 53% 54% 56% 53% 54% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3610853
GSM967853U87-EV human glioblastoma xenograft - Control 23.3898555
GSM967854U87-EV human glioblastoma xenograft - Control 33.3336554
GSM967855U87-EV human glioblastoma xenograft - Control 43.3137155
GSM967856U87-EV human glioblastoma xenograft - Control 53.2466253
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4433754
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4515255
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3035953
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2894453
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3097554
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3977856
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2670653
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3426554
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3153554